Close Menu

NEW YORK (360Dx) — Sienna Cancer Diagnostics said today that it has signed on Shaanxi GaoYuan In Vitro Diagnostic Reagents as its exclusive distribution partner in mainland China.

Under the terms of the deal, GaoYuan has the exclusive right to sell Sienna's in vitro diagnostic for the detection of the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer alongside standard urine cytology testing, in that market.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.